Cytori Therapeutics Inc (NASDAQ:CYTX)’s share price rose 12.1% during mid-day trading on Friday . The stock traded as high as $0.37 and last traded at $0.37. Approximately 850,803 shares traded hands during trading, an increase of 6% from the average daily volume of 805,119 shares. The stock had previously closed at $0.33.

CYTX has been the subject of several analyst reports. Maxim Group set a $10.00 target price on Cytori Therapeutics and gave the stock a “buy” rating in a research report on Saturday, May 13th. B. Riley restated a “buy” rating and set a $2.30 target price on shares of Cytori Therapeutics in a research report on Monday, May 15th. ValuEngine lowered Cytori Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Finally, Zacks Investment Research upgraded Cytori Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 target price for the company in a research report on Tuesday, July 11th.

The company’s market capitalization is $12.84 million. The stock has a 50-day moving average of $0.39 and a 200-day moving average of $1.02.

Cytori Therapeutics (NASDAQ:CYTX) last issued its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.16) by $0.02. Cytori Therapeutics had a negative return on equity of 202.62% and a negative net margin of 450.34%. The company had revenue of $0.90 million for the quarter, compared to the consensus estimate of $2.23 million. During the same quarter last year, the business earned ($0.43) earnings per share. Cytori Therapeutics’s revenue was down 18.2% compared to the same quarter last year. Equities research analysts predict that Cytori Therapeutics Inc will post ($0.60) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Cytori Therapeutics stock. Perkins Capital Management Inc. boosted its holdings in Cytori Therapeutics Inc (NASDAQ:CYTX) by 99.0% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 874,896 shares of the biotechnology company’s stock after purchasing an additional 435,217 shares during the quarter. Cytori Therapeutics comprises 1.1% of Perkins Capital Management Inc.’s holdings, making the stock its 28th largest holding. Perkins Capital Management Inc. owned 2.69% of Cytori Therapeutics worth $962,000 as of its most recent SEC filing. Institutional investors and hedge funds own 11.82% of the company’s stock.

WARNING: This piece of content was reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at

Cytori Therapeutics Company Profile

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

Receive News & Ratings for Cytori Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.